Soon to deploy to the new team on 9/1. All I have been told is will start with non-promo education out in the field. Anyone know the typical Genzyme playbook here for the 1st 6 to 8 weeks? Mostly in field? or Home course learning?
Ignore the DB post. But no need for anxiety. Will be the typical home study/certification crap, not really important because AZ paved the way on EDU. We have a slightly different pathway despite what they may tell you works very similarly to IL5's but with a twist, we can combine FENO measurement with EOS to ID a patient group they can't. Also heard that derm reps will at least get a short refresher on asthma indication for reminders... you will indeed hear more about this by end of month!
Yeah and no statistical significant improvement in FEV1 in Venture with patients with EOS under 300 in 24 wks with a Pvalue .086. No statistical significant reduction in OCS In patients with EOS under 150 in Venture P value .056. Patients with FeNO >/25 <50 ppb had no statistical significant change in FEV1. Patients with FeNO >50ppb has no statistical significant change in FEV1 in 300mg Q2w dosing. Patients had no statistical significant reduction in exacerbations if FENO was <25 P.285 or >/ 50ppb. P .14. In the Quest trial there was a 15% INCREASE in exacerbations on 300mg Q2w dosing for patients with EOS under 150. And a small decrease of only 8% in patients with eos under 150. Seems to do more harm than good in low EOS patients. FeNO levels below 25ppb and eos below 150 there was a 35% INCREASE in exacerbations 300mg Q2w dosing and only a 4 % decrease 200 Q2w dosing. Seems to me the drug has a ton of flaws and poor results in certain patient populations. Select patients will benefit from this drug from what the studies show.
I am interested in a Dupixent sales position for derm. In allergy offices, who gets credit: derm,asthma reps or both? Seems muddy.
